Each MERIT product is a unique construction designed to stimulate antigen-specific protective immune responses including antigen-specific regulatory T-cells, without provoking tissue destructive, cell-mediated inflammatory side effects. Immune tolerance to the patient’s own antigens are maintained and the risks of unwanted side effects, like autoimmunity or compromising the patient’s own ability to fight off infection, are avoided.
Mercia’s corporate strategy is to focus on reducing risk and maximizing return by building a diverse pipeline of novel biological products, either by itself or with partners. Lead candidate discovery is conducted in collaboration with a number of academic experts. Subsequent development is streamlined because each pipeline candidate benefits from the extensive clinical safety and immunopharmacology database previously established with the core technology. A number of the company’s development programs have been initially supported by government funded grants. This has allowed Mercia to retain ownership and maximize its return on investment while developing a diverse pipeline of novel products.
Mercia’s management team is experienced with a proven track record in pharmaceutical research, clinical and product development. Mercia’s team has taken a number of products based on the core technology into and through all stages of clinical development in both the US and Europe.
Mercia has established GMP-compliant manufacture for its products through a strategic alliance with Nova Laboratories, UK. Proprietary aseptic processes have been implemented to provide materials to support clinical trials through commercial batch sizes using fully validated process technology.
Mercia has a growing intellectual property portfolio on it’s unique products.